Global market for pediatric vaccines could reach $23 billion by 2015

The market for pediatric vaccines is projected to hit a value of more than $23 billion globally by 2015, according to a recent market analysis.

The report said that pediatric proprietary vaccines are likely to lead the vaccine market with just under a 60 percent market share by 2015. GlaxoSmithKline is expected to represent close to one quarter of the global market, Fierce Vaccines reports.

According to analysis from Renub Research, between 2005 and 2011, pediatric vaccines doubled their market share. The new report said that the market share will continue to increase, with most of the growth resulting from major vaccines such as Merck's Rotateq, GlaxoSmithKline's Rotarix and Pfizer's Prevnar 7 and Prevnar 13.

Boosters and enhanced pediatric vaccines are predicted to slow in terms of growth because of the maturity of the markets and lower margins. The report projects that diphtheria, tetanus and pertussis vaccines will rise with hepatitis and polio vaccines not far behind.

GlaxoSmithKline, Merck, Sanofi Pasteur, Pfizer and Novartis are the five main companies that dominate the global market for pediatric vaccines. GlaxoSmithKline is far ahead of the others mostly because of its influenza products Hiberix and Fluvarix.

There are vaccines available for 20 different diseases. Ten of the vaccines are recommended for use in all children in the United States, Fierce Vaccines reports.